SYNDAX PHARMACEUTICALS, INC. (NASDAQ:SNDX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
Syndax Pharmaceuticals, Inc. (the Company) held its annual
meeting of stockholders (the Annual Meeting) on May17, 2017. The
results for each of the proposals submitted to a vote of the
Companys stockholders at the Annual Meeting are set forth below.
The proposals set forth below are described in detail in the
Companys definitive proxy statement filed with the Securities and
Exchange Commission on April7, 2017. The voting results were as
follows:
Proposal 1: The Companys stockholders elected both
nominees for director to serve a three-year term until the 2020
Annual Meeting, or until their respective successors are duly
elected and qualified, by the votes set forth in the table below:
|
Nominee |
For | Withheld | BrokerNon-Votes | |||
|
Fabrice Egros |
10,768,003 | 561,937 | 882,338 | |||
|
Pierre Legault |
11,242,559 | 87,381 | 882,338 |
Proposal 2: The Companys stockholders ratified the
selection of Deloitte Touche LLP as the independent registered
public accounting firm of the Company for the fiscal year ending
December31, 2017 by the votes set forth in the table below:
|
For |
Against |
Abstain |
||
|
12,183,958 |
28,145 |
About SYNDAX PHARMACEUTICALS, INC. (NASDAQ:SNDX)
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SYNDAX PHARMACEUTICALS, INC. (NASDAQ:SNDX) Recent Trading Information
SYNDAX PHARMACEUTICALS, INC. (NASDAQ:SNDX) closed its last trading session 00.00 at 14.04 with 899,503 shares trading hands.
